ArticleCureus2025
Small-Cell Lung Cancer Presenting as Hypercalcemia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypercalcemia of malignancy is a common and life-threatening complication in cancer patients, typically seen in advanced breast cancer, multiple myeloma, and non-small-cell lung cancer. In contrast, it is rare in small-cell lung carcinoma (SCLC), where parathyroid hormone levels remain mostly within the normal range despite elevated calcium. We present a case of hypercalcemia in a patient with SCLC and discuss its clinical implications. A 67-year-old male with a significant smoking history and a history of hypertension and atrial fibrillation presented with symptoms, including nausea, vomiting, fatigue, weight loss, excessive thirst, and pleuritic chest pain. Laboratory tests revealed elevated calcium levels (12.2 mg/dL) and signs of organ involvement. Imaging studies suggested metastatic disease, and a liver biopsy confirmed a metastatic neuroendocrine tumor consistent with SCLC. Further investigation showed suppressed parathyroid hormone and low parathyroid hormone-related peptide levels. Lytic bone lesions were not identified on imaging. Despite hydration therapy, the patient's hypercalcemia was refractory, and intravenous zoledronic acid was initiated, improving his encephalopathy. He chose comfort measures and passed away several days later. The patient's hypercalcemia was refractory to hydration, and bisphosphonate therapy was initiated with partial improvement. Despite treatment, the patient's prognosis remained poor, and he transitioned to palliative care. Hypercalcemia in SCLC, though rare, often indicates a poor prognosis and may be related to mechanisms such as cytokine production or bone marrow involvement. The management of hypercalcemia requires rapid intervention, primarily through intravenous hydration. Bisphosphonates and other adjunct therapies may be necessary for refractory cases. Early palliative care discussions are essential, as these patients typically have a limited life expectancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.